This clinical trial is focused on studying the effects of a medication called Tirzepatide on people with Type 2 Diabetes Mellitus. The study compares Tirzepatide, which is given as a solution for injection, with another medication called Dulaglutide. Both medications are designed to help manage blood sugar levels in people with Type 2 Diabetes, a condition where the body does not use insulin properly, leading to high blood sugar levels.
The purpose of the study is to see how well Tirzepatide works compared to Dulaglutide in reducing major cardiovascular events, such as heart attacks or strokes, in people with Type 2 Diabetes who are at high risk for heart problems. Participants in the study will receive either Tirzepatide or Dulaglutide, along with their usual diabetes care, to see which treatment is more effective in preventing these serious heart-related events.
The study will take place over a period of time, during which participants will receive regular injections of either Tirzepatide or Dulaglutide. The researchers will monitor the participants’ health to track any occurrences of heart-related events. The goal is to determine if Tirzepatide is not only as effective as Dulaglutide but also if it might be superior in preventing major cardiovascular events in people with Type 2 Diabetes.
Who Can Join the Study?
You must have a diagnosis of type 2 diabetes, which is a condition where your body has trouble managing blood sugar levels.
You must have confirmed atherosclerotic cardiovascular disease, which means there is a buildup of fats and cholesterol in your artery walls that can restrict blood flow.
Your HbA1c, which is a blood test that shows your average blood sugar levels over the past few months, must be between 7.0% and 10.5%.
Your Body Mass Index (BMI), a measurement used to determine if your weight is healthy for your height, must be 25 or higher.
Who Cannot Join the Study?
You have had a major cardiovascular event, which means a serious heart problem like a heart attack or stroke, within the last 60 days.
You or a family member have a history of medullary thyroid carcinoma (a specific type of thyroid cancer) or multiple endocrine neoplasia syndrome type 2 (a genetic condition that causes tumors in various glands).
You have had a blood transfusion (receiving blood through a vein) or lost a large amount of blood in the 90 days before starting the study.
You have hematological conditions, which are disorders related to the blood, that could make it difficult to measure your HbA1c (a blood test that shows your average blood sugar levels over the past few months).
You have type 1 diabetes, which is a condition where the body does not produce insulin.
You have experienced severe hypoglycemia (dangerously low blood sugar) or hypoglycemia unawareness (not being able to feel the warning signs of low blood sugar) in the last 6 months.
You are currently planning treatment for diabetic retinopathy (damage to the blood vessels in the retina at the back of the eye) or macular edema (swelling in the part of the eye responsible for sharp vision).
You are planning a revascularization procedure, which is a surgery to restore blood flow to the heart, neck (carotid artery), or limbs (peripheral arteries).
You have a history of pancreatitis, which is inflammation of the pancreas.
You have a history of ketoacidosis (a dangerous buildup of acids in the blood) or a hyperosmolar state/coma (a condition where blood sugar is extremely high, causing severe dehydration and loss of consciousness).
You have a known problem with gastric emptying (how fast food leaves your stomach), or you have had or are planning surgery for a gastric outlet obstruction (a blockage at the exit of the stomach), gastric bypass surgery, or other weight-loss surgeries that restrict the stomach.
You have a history of an active or untreated malignancy (cancer), or you have been in remission (a period where cancer signs and symptoms have decreased or disappeared) from a significant cancer for less than 5 years.
Tirzepatide is the experimental medication being tested in this study. It is an injection used to help manage blood sugar levels in people with type 2 diabetes and is being evaluated to see how well it protects against major heart-related problems like heart attack, stroke, or death from heart causes.
Dulaglutide is the comparison medication used in this study. It is an injection that also helps manage blood sugar levels in patients with type 2 diabetes, and it serves as the standard against which the effectiveness of the new treatment is measured.
Type 2 Diabetes Mellitus – This is a chronic condition that affects how the body processes blood sugar. It occurs when the body either resists the effects of insulin or does not produce enough of it to maintain normal glucose levels. Over time, high levels of sugar in the blood can cause damage to various parts of the body. The condition often progresses gradually, starting with insulin resistance. As the disease advances, the pancreas may lose its ability to produce sufficient insulin.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Czechia 
France 
Germany 
Greece 
Hungary 
Italy 
Poland 
Romania 
Slovakia 
Spain 
Sweden 
The Netherlands 
